Clinical Oncology

[The forefront of ovarian cancer therapy: update on PARP inhibitors]


DECEMBER 30, 2020

Clinical Oncology - 2020;7(4)

[In recurrent ovarian cancer, poly(ADP-ribose) polymerase (PARP)-inhibiting agents have transformed the treatment of platinum-sensitive disease. New data support use of PARP inhibitors earlier in the treatment algorithm. We review results from recent phase III trials evaluating PARP inhibitors as treatment and/or maintenance therapy for patients with newly diagnosed ovarian cancer. We discuss the efficacy and safety of these agents in the all-comer and biomarker-selected populations studied in clinical trials, and compare the strengths and limitations of the various trial designs. We also consider priorities for future research, with a particular focus on patient selection and future regimens for populations with high unmet need. Four phase III trials (SOLO-1, PAOLA-1/ENGOT-OV25, PRIMA/ENGOT-OV26 and VELIA/GOG-3005) demonstrated remarkable improvements in progression-free survival with PARP inhibitor therapy (olaparib, niraparib or veliparib) for newly diagnosed ovarian cancer. Differences in trial design (treatment and/or maintenance setting; single agent or combination; bevacizumab or no bevacizumab), patient selection (surgical outcome, biomarker eligibility, prognosis) and primary analysis population (intention-to-treat, BRCA mutated or homologous recombination deficiency positive) affect the conclusions that can be drawn from these trials. Overall survival data are pending and there is limited experience regarding long-term safety. PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.]


  1. Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark
  2. Department of Gynecologic Oncology & Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, USA
  3. Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain
  4. Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, USA
  5. Division of Medical Gynecologic Oncology, European Institute of Oncology IRCCS, University of Milan-Bicocca, Milan, Italy
  6. Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France
  7. Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy



Further articles in this publication

Clinical Oncology

[Contemporary treatment of the malignant tumors of the uterus]


[Yearly around half a million women are diagnosed with uterine cancer worldwide, having leaded to 90,000 deaths in 2018. Endometrial cancers (ECs) are the most common forms of gynaecological malignancies, while sarcomas represent not more than 3% of uterine cancers. In 80-85% of cases ECs are low-grade and diagnosed at an early stage, therefore potentially curable by surgical procedure and postoperative radiotherapy (if necessary). However, the optimal adjuvant management of high risk ECs is still an issue and the recognition of molecular subtypes is generating further clinical investigations in the field. Surgery is also the only curative method in sarcoma-care, but evidences for adjuvant management is scarce and indefinite. Beyond therapeutic benefits, quality of life is also an important factor in modern oncology. Therefore in gynaecological oncology there are intentions like preserving fertility and ovarian function, avoiding systemic lymphadenectomy or using minimal invasive technique to improve the patients’ quality of life without the deterioration of the therapeutic outcome. In the management of advanced endometrial cancer, the biological agents have opened a new era in recent years: pembrolizumab as second line option for MSI-H/dMMR/TMB high EC and the combination of lenvatinib-pembrolizumab for MSS/pMMR EC have been approved. But there are also promising results or ongoing studies with other agents: anti-HER2 therapy for serous EC, cabozantinib-nivolumab or ipilimumab-nivolumab for carcinosarcoma, PARP inhibitors with endocrine therapy for ER positive ECs. Here I present a short summary on the current therapeutic options and the most important ongoing clinical trials in uterine cancer.]

Clinical Oncology

[The highlights of the 2020 ESMO virtual congress]


[The year of 2020 brought unexpected challenges to the healthcare systems all around the globe. Every country had to reorganise their medical priorities to face the COVID19 pandemic. The practice of virtual medicine has expanded in the past years, these new circumstances have increased its speed drastically. Within these unusual circumstances we could take part in the virtual congress of the ESMO 2020 where we were able to hear about the new results of oncology to provide up-to-date care for our patients. Compared to the past years, we did not learn too many breakthrough results, the most of the novelties helped us place our experiences to their ideal place in patient care. The investigations which examined the SARS-CoV2 virus effects on oncologic patients showed grave results, the infection increases the vulnerability and mortality of patients receiving active anticancer therapies or suffering from an active cancer.]

Clinical Oncology

[Tumor-agnostic therapy in oncology]


[Tumor-agnostic therapy is considered as a promising therapeutic approach in oncology, however classification, validation of the targets and standardized methodology for their evaluation is mandatory. The development and approval of the tumor-agnostic drugs should be based on biomarker driven clinical trials. To date three validated biomarkers are known, the high microsatellite instability (MSI-H), the fusion of the neurotrophic-receptor-tyrosine-kinase (NTKR) genes, and the high mutation burden (TMB-H) of the tumors. Pembrolizumab (anti-PD-1 antibody) was the first approved tumor-agnostic drug, the MSI-H status of the tumor was the first indication, then later the TMB-H status was also approved. Larotrectinib and entrectinib are approved for the treatment of NTKR fusion-positive tumours.]

Clinical Oncology

[Heterogeneity in cancer]

KOPPER László, TIMÁR József

[The basic function of cells is to maintain a balance between proliferation and programmed cell death, which allows the cell to perform its specific function. This activity fits closely, partly with neighboring cells and partly with the intercellular population. Errors can occur in the regulation of all this, of course mutations are the most common. Some of these can cause disturbances in cell life, but most mutations do not play an important role. It is well known to distinguish between benignity and malignancy, of which metastasis of tumor cells is the real danger (in fact, a tumor can be considered malignant clinically if it forms metastasis in hematological tumors rather than solids) and this polyclonality interferes with cellular function. It is understandable, therefore, that these two phenomena, metastasis and selection, can be considered the primary targets of therapy. Heterogeneity plays an important role in cell life.]

Clinical Oncology

[The antiemetic treatment of oncologic procedures]

[Nausea and vomiting are multistep pathway controlled by the brain. The emetic impulses come form cortex, as a psyhotic reaction or throught nervus vagus. In the medulla in the area postrema are the specific nuclei concerning to the emetic episodes. Most important neurotransmitters are the serotonin, substance P and dopamins. The chemotherapeutic drugs caused the emesis and vomiting at different frequences. The effect of 5-HT3 and NK-1 receptor antagonist have not are the most important antiemetic role. The fixed oral combination: netupitant and palonosetron (NEPA) increase instead of ensure the patient adherence. Guidelines recommend the antiemetic combinations in different types of chemotherapy. This rewiev covers the specific nausea and vomitig forms: breakthrough, multiday chemotherapy induced, radiation induced and anticipatory emesis. We summarise also the antiemetic therapy in childhood.]

All articles in the issue

Related contents

Hungarian Radiology

[Imaging studies of gynecological tumor staging]


[The imaging staging follows the surgical FIGO staging system in the classification of gynecological carcinomas taking into account the extent of tumor invasion and lymphnode involvement. The most important prognostic factors which influence treatment are the presence of invasive disease and lymphnode metastasis. Imaging techniques for evaluation of gynecological tumor staging are: abdominal and transvaginal ultrasound, computed tomography and magnetic resonance imaging. Transabdominal ultrasound is not a reliable staging modality for gynecological tumors. Computed tomography is useful in the advanced III and IV stages of diseases, but differentiation between stages I and II is difficult. Magnetic resonance imaging showed excellent diagnostic accuracy in determining adnex masses, in the assessment of cervical as well as endometrial and ovarian cancer extension. Magnetic resonance imaging is superior in comparison to computed tomography and ultrasound, in both early and advanced stage disease. Evaluation of lymph-node involvement using computed tomography and magnetic resonance imaging rely only size criteria, which is not reliable indicator of tumor involvement.]

Clinical Oncology

[Treatment of the relapsed epithelial ovarian cancer ]

BOÉR Katalin

[Ovarian cancer remains the most lethal gynaecological cancer and most patients present with advanced FIGO stage disease. Despite optimal upfront surgery and the administration of front-line paclitaxel-carboplatin chemotherapy, approximately two-third of ovarian cancer patients will relapse in the fi rst 3 years. In the last years, the goal in the treatment of ovarian cancer has shifted to maintenance therapy, trying to extend the progression free intervals of the patients. Remarkable advances in the knowledge of molecular biology of relapses led to the introduction the combination of antiangiogenic agent bevacizumab and chemotherapy, which showed to be effective in all phases of the disease, in fi rst-line therapy, as maintenance therapy, and in platinum-sensitive and platinum-resistant recurrence as well. Very recently, a new maintenance therapy, olaparib monotherapy has been introduced into clinical practice to treat platinum-sensitive, relapsed, high-grade serous ovarian cancer. Despite progresses in this therapy, are still some areas of controversy on how to manage epithelial ovarian cancer relapses. The aim of this manuscript is to give an overview on the management of relapsed ovarian cancer in the context of new available therapeutic modalities.]

Hungarian Radiology

[Gynecological malignancies: review of the radiological diagnostics and image-guided therapy - Onco Update 2008]


[The recent results of diagnostical imaging of gynecological tumours and the actual place of interventional radiological methods are discussed. Systematical reviews of articles published during the last year (2007) have been availed to discuss: cervical cancer, endometrial cancer, ovarian cancer, general and special imaging of the female pelvis, different uterine fibroid ablation methods (embolisation and high-intensity focused ultrasound [HIFU]). Experience of gynecological tumour imaging is growing rapidly, therefore, even the current examination algorithm is changing continuously. New diagnostic and therapeutic modalities are making their way into the daily routine. Some examinations become obsolete during the course of time and thus their further application should be avoided. In the meanwhile, some modalities prove their worth and become indespensable during the investigation of a given pathology.]

Lege Artis Medicinae



[It was during the last 15 years when justified by clinical studies the sensitivity/resistance to anticancer chemotherapy was included in the setting of the prognostic factors of the ovarian cancer, while demonstrating a stronger correlation with the outcome than those factors known before. Remission and duration of remission after first-line chemotherapy are the two important components of sensitivity and their combinations measure its grade in a semi-quantitative manner. The chemotherapy sensitivity/resistance approach is based on the observations on ovarian cancer patients treated with platinum based chemotherapy. This agent in repeated adminstrations during the whole course of the disease is still a decisive component of the ovarian cancer chemotherapy. As a consequence there is always “a platinum-free interval”. The prolongation of this platinum-free interval with non-platinum chemotherapy has the potencial of increasing the remission and survival by platinum reinduction administered in the third-line of chemotherapy. In spite of the facts mentioned above, there are centers which prefer the early re-administration of taxan/platinum combination to the prolongation of platinum- free interval and expose their patients to an elevated risk of cumulative, in the first-line non-haematological toxicity.The neurotoxicity can deteriorate the quality of life and the parenchymal laesion of kidneys can prevent further chemotherpy.]

Clinical Oncology

[First-line treatment of epithelial ovarian cancer]


[The restructuration of Hungarian oncological attendance and medicinal fi nancing resulted in the more intensive participation of clinical oncologists in the therapy of patients with ovarian cancer. The aim of the authors was not to defi ne the taxative therapeutic recommendations, but to give an overview on the development of the therapy and to introduce the deliberation aspects and therapeutic alternatives. While the primary and secondary prevention have developed in case of cervical cancer - with the possibility of eradication - the improvement of surgical techniques and clinical oncological treatments may result in the decrease of mortality in ovarian cancer. It is important to emphasis that only the appropriately aligned application of the two therapeutic modalities can lead to the desired outcome. It has become clear by the end of the ‘90s, that paclitaxel-carboplatin combination is the standard chemotherapy against ovarian cancer. Alternative cytostatic treatments like intraperitoneal treatment and triplets were not breakthroughs. The dose intensive treatment increased the survival rates besides good tolerability, however the results require further confi rmation. Neoadjuvant therapy should be considered in case of patients with advanced and metastatic disease in selected cases. Recently, therapeutic use of angiogenesis inhibition comes with signifi cant improvement. Bevacizumab is the fi rst of targeted therapies, and studies on the effectiveness of similar compounds are under way.]